LGND Nov 2019 110.000 call

OPR - OPR Delayed Price. Currency in USD
0.4000
0.0000 (0.00%)
As of 10:46AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close0.4000
Open0.5300
Bid0.0000
Ask0.0000
Strike110.00
Expire Date2019-11-15
Day's Range1.4000 - 2.2300
Contract RangeN/A
Volume7
Open InterestN/A
  • Business Wire

    Ligand Pharmaceuticals Ranked in Deloitte’s 2019 Technology Fast 500™

    Ligand Pharmaceuticals Incorporated (LGND) today announced it ranked in Deloitte’s Technology Fast 500™, a listing of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America now in its 25th year. “This is the third time Ligand has been included in the Technology Fast 500, and we are very pleased once again to be recognized by Deloitte for our rapid revenue growth,” said John Higgins, Chief Executive Officer of Ligand.

  • Business Wire

    Ligand Presents Positive Results from Phase 1 Clinical Trial of Captisol-enabled Iohexol

    Presentation at the American Society of Nephrology Kidney Week 2019

  • Business Wire

    Ligand to Participate in the Stephens 2019 Nashville Investment Conference

    Ligand Pharmaceuticals Incorporated (LGND) announces that the company is scheduled to participate in the Stephens 2019 Nashville Investment Conference in Nashville, Tennessee. Matt Korenberg, CFO will attend for Ligand. Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines.

  • Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down
    Zacks

    Ligand's (LGND) Q3 Earnings Miss Estimates, EPS View Down

    Ligand (LGND) reports lower-than-expected third-quarter 2019 earnings. It also lowers outlook for 2019 earnings. However, revenues were better than expected.

  • Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals
    CNW Group

    Talem Therapeutics accesses the OmniAb® platform from Ligand Pharmaceuticals

    VICTORIA , Nov. 5, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (IPATF), an industry leader in the discovery of novel, therapeutic antibodies, announces that Talem Therapeutics, a wholly-owned subsidiary, has entered into a worldwide OmniAb® platform license agreement with Ligand Pharmaceuticals (LGND). This license enables Talem to access Ligand's unique OmniAb platform for use with Talem's leading antibody discovery capabilities. Under the license, Talem has the right to develop and partner fully human antibodies in OmniRat®, OmniFlic®, OmniMouse®, OmniChicken®, and OmniClic™.

  • Business Wire

    Ligand Reports Third Quarter 2019 Financial Results

    Conference Call Begins at 4:30 p.m. Eastern Time Today

  • Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for
    Zacks

    Analysts Estimate Ligand Pharmaceuticals (LGND) to Report a Decline in Earnings: What to Look Out for

    Ligand (LGND) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • Is Ligand Pharmaceuticals Inc. (LGND) Going To Burn These Hedge Funds ?
    Insider Monkey

    Is Ligand Pharmaceuticals Inc. (LGND) Going To Burn These Hedge Funds ?

    Is Ligand Pharmaceuticals Inc. (NASDAQ:LGND) a good investment right now? We check hedge fund and billionaire investor sentiment before delving into hours of research. Hedge funds spend millions of dollars on Ivy League graduates, expert networks, and get tips from investment bankers and industry insiders. Sure they sometimes fail miserably, but their consensus stock picks […]

  • Business Wire

    Ligand to Report Third Quarter 2019 Results on November 5th

    Ligand Pharmaceuticals Incorporated announced today plans to report third quarter 2019 financial results on November 5, 2019. Ligand’s CEO John Higgins, President and COO Matt Foehr and Executive Vice President and CFO Matt Korenberg will host the conference call.

  • Business Wire

    Ligand Appoints Pharmaceutical Executive Sarah Boyce to its Board of Directors

    Ligand Pharmaceuticals Incorporated (LGND) (“Ligand” or “the Company”) announces the appointment of Sarah Boyce to the Company's Board of Directors, effective today. Ms. Boyce currently serves as President and CEO of Avidity Biosciences, Inc., a privately held biotechnology company pioneering the use of antibody-oligonucleotide conjugates (AOC™) to treat rare muscle disorders and other serious diseases. Ms. Boyce's appointment increases the number of Ligand directors to nine.

  • Who Has Been Buying Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares?
    Simply Wall St.

    Who Has Been Buying Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Shares?

    We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The...

  • CNW Group

    ImmunoPrecise Strengthens Board of Directors with Antibody Business Leader, Brian Lundstrom

    VICTORIA , Oct. 3, 2019 /CNW/ - IMMUNOPRECISE ANTIBODIES LTD. (the "Company" or "IPA") (TSX VENTURE: IPA) (OTC QB: IPATF) a provider of best-in-class therapeutic antibody discovery capabilities for the global industry, today announced the appointment of Brian Lundstrom to the company's Board of Directors. Trained in immunology and international business, Mr. Lundstrom has over 30 years' experience from mostly publicly traded companies with a focus on antibody therapeutics.

  • GlobeNewswire

    Sermonix Doses First Patient in Phase 2 Clinical Trial of Lasofoxifene for Targeted Precision Medicine Treatment of Women With ESR1 Mutations in Metastatic Breast Cancer

    Sermonix Pharmaceuticals Inc., a privately held biopharmaceutical company focused on the development of female-specific oncology products in the precision medicine metastatic breast cancer arena, today announced the enrollment and dosing of the first patient into a Phase 2 clinical trial of its lead investigational drug, lasofoxifene. The open-label, randomized, multi-center Evaluation of Lasofoxifene in ESR1 Mutations (ELAINE, NCT03781063) study will assess the efficacy of oral lasofoxifene versus intramuscular fulvestrant for the treatment of postmenopausal women with locally advanced or metastatic estrogen receptor-positive (ER+)/HER2- breast cancer with an ESR1 mutation and progression-free survival as the primary endpoint.

  • Ligand (LGND) Surges: Stock Moves 6.3% Higher
    Zacks

    Ligand (LGND) Surges: Stock Moves 6.3% Higher

    Ligand (LGND) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.

  • MarketWatch

    Ligand Pharmaceuticals approves new $500 million stock buyback program

    Ligand Pharmaceuticals Inc. disclosed Thursday that a new program to repurchase up to $500 million worth of stock over the next three years was approved by the company's board. Based on Wednesday's stock closing price of $91.80, the biopharmaceutical company could buy back up to 5.45 million shares, or 28.6% of the shares outstanding as of Aug. 7. The company said its previous $350 million stock repurchase program was terminated after it had bought back 2.97 million shares for about $350 million. Separately, Ligand disclosed that it had entered into a commercial platform license agreement with Hong Kong-based Kira Pharmaceuticals, which is focused on treatments for immunological diseases and cancer immunotherapy, in which Kira will be able to use OmniAb platform rodents and birds to discover fully human mono- and bispecific antibodies. Ligand will be eligible to receive milestone payments and tiered royalties for each product delivering an OmniAb antibody. The stock, which was still inactive in premarket trading, has slumped 32.4% year to date while the S&P 500 has gained 19.7%.

  • Why Is Ligand (LGND) Down 0.9% Since Last Earnings Report?
    Zacks

    Why Is Ligand (LGND) Down 0.9% Since Last Earnings Report?

    Ligand (LGND) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

  • Retrophin Down on Neurological Disorder Drug Study Failure
    Zacks

    Retrophin Down on Neurological Disorder Drug Study Failure

    Retrophin (RTRX) declines as the late-stage study on a rare neurological disorder candidate failed to achieve its main goal.

  • 3 Top Biotech Stocks to Buy in August
    Motley Fool

    3 Top Biotech Stocks to Buy in August

    In the high-risk world of biotech investing, there are no guarantees of success. Still, sometimes investors can find places where the odds look reasonable enough to consider buying shares.

  • Thomson Reuters StreetEvents

    Edited Transcript of LGND earnings conference call or presentation 30-Jul-19 1:00pm GMT

    Q2 2019 Ligand Pharmaceuticals Inc Earnings Call

  • GuruFocus.com

    Ligand Pharmaceuticals Inc (LGND) CEO John L Higgins Bought $176,582 of Shares

    CEO of Ligand Pharmaceuticals Inc (30-Year Financial, Insider Trades) John L Higgins (insider trades) bought 1,850 shares of LGND on 07/31/2019 at an average price of $95.45 a share. Continue reading...

  • Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat
    Zacks

    Ligand (LGND) Stock Down Despite Q2 Earnings & Sales Beat

    Ligand (LGND) reports better-than-expected second-quarter 2019 results and maintains view for the full year.

  • Ligand Pharmaceuticals Incorporated (LGND) Q2 2019 Earnings Call Transcript
    Motley Fool

    Ligand Pharmaceuticals Incorporated (LGND) Q2 2019 Earnings Call Transcript

    LGND earnings call for the period ending June 30, 2019.

  • Benzinga

    Long-Time Ligand Short Increases Position As Shares Fall 11% On Earnings

    Ligand Pharmaceuticals Inc. (NASDAQ: LGND) shares are down 10.5% on Tuesday following the company’s earnings report, but one of the company’s most vocal critics and short sellers is leaning into its bearish trade. On Tuesday, Ligand short seller Lemelson Capital Management said the firm has been adding to its short position against Ligand and is calling for an investigation into alleged crimes committed by the company. “Sadly, investors have been ruined by Ligand’s alleged scheme while the SEC has ignored the red flags and botched opportunities for a proper investigation of the company,” Lemelson Capital’s Chief Investment Officer Fr.